AEON
AEON Biopharma, Inc.
1W: -1.8%
1M: -9.2%
3M: +12.4%
YTD: -1.8%
1Y: +45.3%
$1.07
-0.06 (-5.31%)
After Hours: $1.10 (+0.03, +3.27%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$12.7M
52W Range0.375-1.45
Volume25,184
Avg Volume162,152
Beta0.71
Dividend—
Analyst Ratings
Company Info
CEORobert Bancroft
Employees5
SectorHealthcare
IndustryBiotechnology
IPO Date2023-07-24
Websiteaeonbiopharma.com
4040 Macarthur Boulevard
Newport Beach, CA 92614
US
Newport Beach, CA 92614
US
949-354-6499
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
Latest News
AEON Biopharma (NASDAQ:AEON) Trading 1.8% Higher – Here’s Why
AEON Biopharma appoints John Bencich as CFO
AEON Biopharma Appoints John Bencich as Chief Financial Officer
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BARCLAYS PLC | 152,387 | $11.50 | 2027-12-31 | |
| Oh Chad | A-Award | 1,316,872 | — | 2026-03-04 |
| Wilson Alexander Bla | A-Award | 1,316,872 | — | 2026-03-04 |
| Sy Jennifer | A-Award | 925,925 | — | 2026-03-04 |
| Oh Chad | A-Award | 862,500 | — | 2026-02-17 |